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Abstract
Introduction: Patients with metastatic mucoepidermoid carcinoma of salivary glands have a poor
outcome. The epidermal growth factor receptor protein is overexpressed in approximately 70%
of mucoepidermoid carcinoma patients and may represent a therapeutic target. However, whether
treatment with anti-epidermal growth factor receptor agents is effective is unclear and clinical trials
are difficult due to the rarity of the disease. Here we assessed the activity of cetuximab in
mucoepidermoid carcinoma on a molecular basis.
Case presentation: We present the case of a 40-year old Caucasian man with a mucoepidermoid
carcinoma of the major salivary glands who developed distant bone and visceral metastases despite
platinum-based chemotherapy. Epidermal growth factor receptor was overexpressed and
fluorescence in situ hybridization analysis demonstrated a chromosome 7 polysomy. The patient
was treated with the monoclonal antibody cetuximab in combination with cisplatin. After 11 doses
of cetuximab, the patient developed brain metastases but evidence of response was documented
at all extracranial metastatic sites.
Conclusion:  This case report indicates that cetuximab can be active in mucoepidermoid
carcinoma and may restore sensitivity to cisplatin in platinum-treated patients. Cetuximab does not
cross the blood brain barrier and may select a metastatic clone to home the central nervous system
while responding at other sites.
Introduction
Salivary gland carcinomas (SGC) are rare neoplasms that
account for less than 1% of all human cancers. Among
SGCs, the mucoepidermoid carcinoma (MEC) is the most
common primary neoplasm, representing approximately
30% of salivary malignancies. MEC is histologically char-
acterized by a heterogeneous cellular composition,
including squamoid (epidermoid), mucus producing and
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intermediate cells. The tumor grade is defined according
to five histological features (the cystic component, neural
invasion, necrosis, number of mitoses and anaplasia) and
is important in classifying low, intermediate and high
grade neoplasms [1]. High-grade MEC is an aggressive dis-
ease with a 5-year survival rate of 25 to 30%. Although the
disease is often localized at presentation and rarely
presents with metastases, MEC tends to recur locally and
to metastasize. The initial treatment of MEC, regardless of
grade, is essentially based on surgical resection and even-
tually on adjuvant radiotherapy. Due to the rarity of the
disease, current literature is scarce and often reflects data
from small and heterogeneous series. Thus, no guidelines
are available to support the clinician's decision and the
management of metastatic MEC remains challenging.
Local recurrences not amenable to further loco-regional
treatments and metastatic disease are treated with sys-
temic chemotherapy. Single-agent or combination chem-
otherapy with cisplatin, fluorouracil and/or paclitaxel has
demonstrated activity in published series but overall
response rates are unsatisfactory and of short duration
[2,3]. Overexpression of the human epidermal growth fac-
tor receptor (HER) family of oncoproteins, HER1/epider-
mal growth factor receptor (EGFR) and HER2, has been
described in approximately 70% of salivary gland carcino-
mas including MEC and adenoid cystic carcinoma [4] but
few studies have evaluated the therapeutic relevance of an
anti-EGFR/HER2 strategy in these neoplasms. Here we
report the case of a metastatic MEC of the major salivary
glands that was refractory to platinum-containing regi-
mens and was treated with the anti-EGFR monoclonal
antibody cetuximab in combination with chemotherapy.
Case presentation
In January 2006, a 40-year-old Caucasian man underwent
a non radical resection of a high-grade MEC of the right
submandibular salivary gland at another institution. Post-
operative radiotherapy was not advised, and three months
later, the disease progressed locally and in the cervical
lymph nodes. At our institution, he was then treated with
three cycles of the paclitaxel, cisplatin, fluorouracil (TPF)
regimen; however, the disease progressed systemically
with diffuse subcutaneous neoplastic infiltrates. He there-
fore received a second line chemotherapy with carbopla-
tin and vinorelbine, but further progression occurred after
two cycles. The total body [18F]fluorodeoxyglucose (FDG)
positron emission tomography (PET) with fusion of CT-
scan imaging (CT-PET) documented the onset of medias-
tinal adenopathies, pleural effusion and multiple bone
lesions (Figure 1). Immunohistochemical analysis of the
primary tumor specimen showed an intense and diffuse
staining for EGFR. Cytogenetic fluorescence in situ
hybridization (FISH) analysis for the EGFR gene was neg-
ative for gene amplification but demonstrated polysomy
of the chromosome 7p12 (CEP7) with an average of five
copies (range 3–7) of chromosome 7 per cell. Analysis of
EGFR activating mutations was not performed. The
patient was then treated with cetuximab (Erbitux®, Merck
KGaA, Darmstadt, Germany), administered iv at a loading
dose of 400 mg/m2 over 2 hours and then at 250 mg/m2
weekly in combination with cisplatin (100 mg/m2) every
21 days as described by Herbst et al. [5]. After the second
cycle, a minor response was documented clinically and by
CT-PET, along with the onset of a WHO grade 2 classic
anti-EGFR-dependent acneiform rash; the patient contin-
ued treatment with four complete cycles of cisplatin and
11 doses of cetuximab. He also experienced WHO grade 1
paresthesias of the extremities and mild renal function
impairment. Both these side effects were attributed to cis-
platin.
In September 2006, during the treatment, the patient
experienced recurrent convulsive seizures that required
hospitalization. Neurologic examination was normal. An
EEG showed a diffuse slowing of background activity.
Rare and brief sequences of slow waves were recorded on
the central regions, bilaterally. A brain CT-scan demon-
strated the presence of at least five bilobar, parenchymal,
metastatic lesions (Figure 2). Total-body CT-PET docu-
mented a partial response (PR > 50%) of all the evaluable
extracranial metastatic lesions (Figure 1). Response was
assessed according to the RECIST criteria for radiological
CT imaging and to the 1999 EORTC recommendations for
the use of [18F]fluorodeoxyglucose PET.
The patient received palliative whole brain irradiation up
to 30 Gy with a daily 3 Gy fractionation and was then
returned to supportive care.
In October 2006, neoplastic pleural effusion worsened
and the patient died of rapidly progressive disease.
Discussion
The epidermal growth factor receptor (EGFR) signalling
pathway is involved in the physiological cell differentia-
tion of secretory acinus and related ducts, the functional
unit of salivary glands. Immunohistochemical studies
demonstrated different degrees of EGFR expression in sev-
eral salivary gland carcinomas, including MECs and ade-
noid cystic carcinomas (ACCs). In MECs, the percentage
of membrane staining of EGFR is approximately 77%
which is higher than in normal tissue [4]. EGFR overex-
pression is related to a poorer prognosis and a more
aggressive behaviour of the disease but its overall prog-
nostic value has not been completely established [3,6].
Thus, the development of anti-HER2 or anti-EGFR strate-
gies in salivary gland carcinomas could represent a reason-
able approach based on a biological rationale. In head
and neck squamous cell carcinoma (HNSCC), the anti-
EGFR monoclonal antibody cetuximab has been provenJournal of Medical Case Reports 2008, 2:320 http://www.jmedicalcasereports.com/content/2/1/320
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Total body computed tomography-positron emission tomography with [18F]fluorodeoxyglucose before (left panel) and after  (right panel) treatment Figure 1
Total body computed tomography-positron emission tomography with [18F]fluorodeoxyglucose before (left 
panel) and after (right panel) treatment. Metabolically active neoplastic disease is located by high standardized uptake 
value of tracer: maximum standardized uptake value values are reported for each lesion before and after treatment.Journal of Medical Case Reports 2008, 2:320 http://www.jmedicalcasereports.com/content/2/1/320
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to prolong overall survival in combination with radiother-
apy [7] and to enhance response rates in recurrent/meta-
static disease in combination with cisplatin or
fluorouracil [8]. Whether cetuximab can overcome plati-
num resistance in cisplatin-pretreated patients remains
controversial [9,10]. Among predictive factors of response
to anti-EGFR strategies in HNSCC, EGFR gene amplifica-
tion status is predictive of sensitivity to the EGFR-tyrosine
kinase inhibitor, gefitinib [11]. On the other hand, no
activating mutations in the EGFR gene are associated with
response to anti-EGFR strategies [12].
To date, only a few, small clinical trials have investigated
the antitumor activity of anti-EGFR targeted agents in the
salivary gland neoplasms. In a phase II study of cetuximab
monotherapy in 22 patients with recurrent/metastatic sal-
ivary gland carcinomas, including two MECs, 11 patients
had stable disease, seven of which remained progression-
free for over 6 months. None of these patients displayed
EGFR amplification or chromosome 7 polysomy [13]. In
a recent phase II study of lapatinib, a dual inhibitor of
EGFR and HER2, in recurrent/metastatic salivary gland
carcinomas, including two MECs, Agulnik et al. demon-
strated disease stabilization that lasted for more than 6
months in 36% of the patients; no objective responses
were observed. None of the patients in the cohort with
disease stabilization, however, were patients with MEC
[14].
In our report, the patient was pretreated with two lines of
platinum-containing chemotherapy with no evidence of
response; a response was only observed upon treatment
with cisplatin along with cetuximab. We do not know
whether the response was due to cetuximab alone or due
to a synergistic effect with the restoration of cisplatin sen-
sitivity. The chromosome 7 polysomy, documented in the
patient, may account for increased protein expression at
the membrane level and clinical response. However, a
clear genotype/phenotype correlation cannot be estab-
lished on the basis of only this data. Finally, a mixed pat-
tern of central nervous system (CNS) progression and
systemic response was concomitantly observed in our
patient. Such an effect is often seen in metastatic breast
cancer patients treated with trastuzumab who develop
CNS metastases while responding at different metastatic
sites. The creation of a CNS sanctuary for cancer cells
results from the inability of trastuzumab to cross the
blood-brain barrier due to its relatively high molecular
weight; this mechanism presumably also applies to cetux-
imab in different neoplastic conditions, as our case dem-
onstrates.
Conclusion
In conclusion, this case report indicates cetuximab func-
tion in a recurrent and metastatic MEC of the salivary
glands. EGFR expression is a prerequisite for cetuximab
use but EGFR gene amplification, or at least chromosome
7 polysomy, seems to be necessary for elicitation of bio-
logical activity. Our findings also emphasize the impor-
tance of CT-PET in monitoring neoplastic diseases during
molecular targeted therapies. The inability of cetuximab
to cross the blood-brain barrier and the consequent devel-
opment of CNS metastases during treatment is a subject of
concern that requires further study.
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